… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a … its clinical stage pipeline programs and the Axiomer ® RNAediting platform. ProQR leadership will highlight key …
… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … Medicines Symposium on June 29, 2022 as part of the RNAEditing track. The Company’s presentation will be webcast …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… company dedicated to changing lives through transformative RNA therapies, today announced several presentations … highlighting the Company’s proprietary Axiomer ® RNAediting technology platform at upcoming scientific and …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform, today reported its financial …
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P